Bill Text: NY A08566 | 2017-2018 | General Assembly | Amended
Bill Title: Relates to directing the commissioner of the department of health to promulgate rules and regulations promoting recovery from opioid abuse and reducing diversion of addiction medicines.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Introduced - Dead) 2018-01-22 - print number 8566a [A08566 Detail]
Download: New_York-2017-A08566-Amended.html
STATE OF NEW YORK ________________________________________________________________________ 8566--A 2017-2018 Regular Sessions IN ASSEMBLY July 10, 2017 ___________ Introduced by M. of A. CUSICK -- read once and referred to the Committee on Alcoholism and Drug Abuse -- recommitted to the Committee on Alco- holism and Drug Abuse in accordance with Assembly Rule 3, sec. 2 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee AN ACT to amend the public health law, in relation to directing the commissioner of the department of health to promulgate rules and regu- lations promoting recovery from opioid abuse and reducing diversion of addiction medicines The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. The public health law is amended by adding a new section 2 3309-b to read as follows: 3 § 3309-b. Promoting recovery from opioid abuse and reducing diversion 4 of addiction medicines. 1. The commissioner shall, in consultation with 5 the office of alcoholism and substance abuse services, promulgate rules 6 and regulations pertaining to individual physicians and group practices 7 including, but not limited to, physician's office-based opioid treat- 8 ment, opioid treatment programs and any other treatment practices serv- 9 ing more than fifty patients at a time who have a primary or secondary 10 diagnosis of opiate misuse or addiction. Such rules and regulations 11 shall at a minimum include the following provisions: 12 (a) All patients seeking treatment for opiate use disorder shall be 13 given an orientation including factual information and an easily under- 14 stood explanation of each addiction medication option approved by the 15 United States food and drug administration. Such education must be docu- 16 mented in the patient record along with documentation regarding the 17 patient's choice of one of the medication options or none of them. Such 18 documentation shall be signed by the patient, or the commissioner may 19 specify some other form of documentation showing that the medical EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD13158-03-8A. 8566--A 2 1 provider made a good faith effort to obtain such informed consent from 2 the patient; 3 (b) If a patient chooses an addiction medication not available through 4 the medical practitioner, such practitioner must make a referral to a 5 treatment setting where the patient can access his or her preferred 6 medication option; 7 (c) The medical provider shall utilize the level of care for alcohol 8 and drug treatment referral web application provided by the office of 9 alcoholism and substance abuse services or another patient assessment 10 instrument approved by the office of alcoholism and substance abuse 11 services to help determine an appropriate level of patient care; 12 (d) In the event that the patient using opiates declines to engage in 13 treatment the medical provider shall provide such patient with informa- 14 tion about accessible harm reduction services; 15 (e) Treatment counseling shall be provided to all individuals for whom 16 an addiction medication is prescribed or dispensed. Such treatment coun- 17 seling may be provided by a qualified addiction professional, as deter- 18 mined by the office of alcoholism and substance abuse services, employed 19 by the medical practice or through a contract with an office of alcohol- 20 ism and substance abuse services certified treatment program; 21 (f) The medical provider shall develop a treatment plan for each 22 patient and such plan shall be reviewed, at a minimum, every six months. 23 The standards for developing individual treatment plans shall be deter- 24 mined by the office of alcoholism and substance abuse services and shall 25 be consistent with the standards used in other office of alcoholism and 26 substance abuse services licensed outpatient treatment programs; 27 (g) The medical provider shall inform patients about available peer 28 recovery support services; and 29 (h) When an addiction medication is not taken under direct clinical 30 supervision, the medical provider shall utilize diversion control prac- 31 tices to ensure such medication is taken as prescribed and not diverted. 32 Such practices shall be determined by the commissioner and shall 33 include: 34 (i) limits on the amount of medication prescribed and the number of 35 refills given to a patient until such patient has established a pattern 36 of reliability; and 37 (ii) minimum toxicology screening standards. 38 2. For all medical providers subject to these rules and regulations, 39 the commissioner shall ensure that providers are monitored for compli- 40 ance. Such monitoring shall be done directly by the department or by an 41 independent organization specified by the commissioner. 42 3. The commissioner shall establish appropriate penalties for medical 43 practitioners who fail to comply with such rules and regulations promul- 44 gated under subdivision one of this section. 45 § 2. This act shall take effect January 1, 2019; provided, however, 46 that effective immediately, the addition, amendment and/or repeal of any 47 rule or regulation necessary for the implementation of this act on its 48 effective date are authorized to be made and completed on or before such 49 effective date.
